Permanence Bio

We Protect the Genome

Permanence Bio is a biotech company in San Francisco, United States, founded in 2024. It has raised $35.0M across 2 rounds, most recently a $20.0M Series A in January 2026.

Employees
1–10
Founded
2024
Business Model
B2B
Total Funding
$35.0M
Last Round
$20.0M Series AJan 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. to use credits for reveals, or explore the API.

About

Permanence Bio creates medicines to shield DNA from damage associated with aging, disease, and cancer. It combines screening at scale with AI to find therapies, focusing its work on protection from DNA damage. Its research connects the search for therapies with the goal of addressing damage behind these conditions.

Funding History

Data from Indexed.vcUpdated
Series ASeries AJan 2026
$20.0M

1 more funding event

  • Pre-seed20241 investor

Funding: Pre-Seed through Series A. Amounts, valuations, and investors where available.

Investors

Companies in related industries

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Permanence Bio on Indexed.vc
<a href="https://indexed.vc/companies/permanence-bio"><img src="https://indexed.vc/api/badge/company/permanence-bio" alt="Permanence Bio on Indexed.vc" width="260" height="76" /></a>